Leerink Partnrs Lifts Earnings Estimates for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q3 2025 EPS estimates for shares of Gilead Sciences in a research note issued on Monday, July 14th. Leerink Partnrs analyst D. Graybosch now expects that the biopharmaceutical company will earn $2.37 per share for the quarter, up from their previous estimate of $2.26. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share. Leerink Partnrs also issued estimates for Gilead Sciences' Q4 2025 earnings at $1.98 EPS.

GILD has been the topic of several other research reports. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Oppenheimer reduced their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Finally, Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. Nine research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $111.38.

Gilead Sciences Price Performance

NASDAQ GILD traded down $1.05 on Tuesday, hitting $108.80. 4,275,152 shares of the company were exchanged, compared to its average volume of 7,668,883. The firm has a 50 day moving average of $108.37 and a two-hundred day moving average of $104.94. The company has a market cap of $135.34 billion, a P/E ratio of 22.91, a P/E/G ratio of 0.71 and a beta of 0.29. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. Gilead Sciences has a 1-year low of $70.78 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm's quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.32) EPS.

Institutional Trading of Gilead Sciences

A number of large investors have recently bought and sold shares of the business. Chicago Capital LLC increased its stake in Gilead Sciences by 2.8% during the 2nd quarter. Chicago Capital LLC now owns 4,121 shares of the biopharmaceutical company's stock worth $457,000 after purchasing an additional 113 shares in the last quarter. One Wealth Advisors LLC increased its stake in Gilead Sciences by 34.8% during the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company's stock worth $1,016,000 after purchasing an additional 2,364 shares in the last quarter. Trivium Point Advisory LLC increased its stake in Gilead Sciences by 294.4% during the 2nd quarter. Trivium Point Advisory LLC now owns 7,242 shares of the biopharmaceutical company's stock worth $803,000 after purchasing an additional 5,406 shares in the last quarter. G&S Capital LLC bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $2,586,000. Finally, Capital Investment Advisors LLC increased its stake in Gilead Sciences by 1.5% during the 2nd quarter. Capital Investment Advisors LLC now owns 358,139 shares of the biopharmaceutical company's stock worth $39,707,000 after purchasing an additional 5,133 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $978,880.80. This trade represents a 35.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction that occurred on Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the sale, the chief executive officer owned 615,725 shares in the company, valued at $68,006,826.25. This represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 72,000 shares of company stock valued at $7,844,775. Insiders own 0.27% of the company's stock.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.90%. Gilead Sciences's dividend payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.